Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata

The study assessed the efficacy and safety of ritlecitinib, a JAK3/TEC family kinase inhibitor, in 105 Asian participants with alopecia areata (AA) from the ALLEGRO-2b/3 and ALLEGRO-LT clinical trials. Participants were divided into two groups: 58 in the 50-mg group and 47 in the 200/50-mg group. Results indicated that ritlecitinib effectively improved hair regrowth, with a significant number achieving a Severity of Alopecia Tool (SALT) score of ≤20 by Month 24. The safety profile was consistent with previous studies, showing no new safety concerns. Despite the small sample size limiting generalizability, the study supports ritlecitinib as a viable treatment option for AA in Asian populations, demonstrating sustained efficacy in scalp, eyebrow, and eyelash regrowth with a favorable benefit-risk profile for long-term use in individuals aged ≥12 years with severe AA.